Ibuprofeno Braun (Ibuprofen)

Ibuprofen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for producing prostaglandins. By lowering prostaglandin levels, it diminishes pain signaling, reduces fever, and limits inflammatory swelling at the site of tissue injury.

The specific dose and infusion rate of Ibuprofeno Braun are determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Healthcare professionals should follow local guidelines and product labeling.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ibuprofeno Braun offers rapid systemic exposure via intravenous delivery, which can be advantageous in acute care when oral administration is not feasible. Compared with oral NSAIDs, it provides more predictable plasma concentrations but shares a similar safety profile regarding gastrointestinal, renal, and cardiovascular risks.

Ibuprofeno Braun must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use if the product appears discolored or contains particles.

The medication is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and total dose are calculated by the prescriber and administered through a suitable IV line, following aseptic technique and standard infusion protocols.

Serious risks include gastrointestinal bleeding or ulcer perforation, severe renal impairment, hypersensitivity reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for signs of these events.

Ibuprofeno Braun is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal bleeding or ulcer disease, severe renal or hepatic impairment, and in those who have experienced previous severe allergic reactions to similar agents.